Literature DB >> 2335046

Bayesian forecasting of serum gentamicin concentrations in intensive care patients.

K A Rodvold1, R D Pryka, P G Kuehl, R A Blum, P Donahue.   

Abstract

This study retrospectively evaluated the predictive performance of a 1-compartment Bayesian forecasting program in adult intensive care unit (ICU) patients with stable renal function. A comparison was made of the reliability of 3 sets of population-based parameter estimates and 2 serum concentration monitoring strategies. A larger mean error for prediction of peak gentamicin concentrations was seen with literature-derived parameters than when ICU population-based parameter estimates were used. Bias and precision improved when non-steady-state peak and trough concentrations were used to predict those at steady-state; the addition of steady-state values did not provide additional information for predictions once non-steady-state feedback concentrations were incorporated. The addition of 4 serial gentamicin concentrations obtained at both non-steady-state and steady-state did not noticeably improve the predictive performance. The results demonstrate that initial ICU pharmacokinetic parameter estimates for a 1-compartment Bayesian model provide accurate prediction of steady-state gentamicin concentrations. Prediction bias and precision showed the greatest improvement when non-steady-state gentamicin concentrations were used to determine individualised pharmacokinetic parameters.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2335046     DOI: 10.2165/00003088-199018050-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  25 in total

1.  Evaluation of a two-compartment Bayesian forecasting program for predicting vancomycin concentrations.

Authors:  K A Rodvold; R D Pryka; M Garrison; J C Rotschafer
Journal:  Ther Drug Monit       Date:  1989       Impact factor: 3.681

2.  Individualizing vancomycin dosage regimens: one- versus two-compartment Bayesian models.

Authors:  R D Pryka; K A Rodvold; M Garrison; J C Rotschafer
Journal:  Ther Drug Monit       Date:  1989       Impact factor: 3.681

3.  Predicted and measured aminoglycoside pharmacokinetic parameters in critically ill patients.

Authors:  E Hassan; J D Ober
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

4.  Inadequacy of standard aminoglycoside loading doses in acutely ill patients.

Authors:  L Chelluri; M S Jastremski
Journal:  Crit Care Med       Date:  1987-12       Impact factor: 7.598

5.  The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia.

Authors:  R D Moore; C R Smith; P S Lietman
Journal:  J Infect Dis       Date:  1984-03       Impact factor: 5.226

6.  Bayesian approaches in pharmacokinetic decision making.

Authors:  G E Schumacher; J T Barr
Journal:  Clin Pharm       Date:  1984 Sep-Oct

7.  Drug use in a surgical intensive care unit.

Authors:  J F Dasta
Journal:  Drug Intell Clin Pharm       Date:  1986-10

Review 8.  Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients.

Authors:  B E Kreger; D E Craven; W R McCabe
Journal:  Am J Med       Date:  1980-03       Impact factor: 4.965

9.  Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive care.

Authors:  P W Niemiec; M D Allo; C F Miller
Journal:  Arch Surg       Date:  1987-02

Review 10.  The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients.

Authors:  A Bodenham; M P Shelly; G R Park
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

View more
  10 in total

1.  Population pharmacokinetic parameters for Bayesian monitoring of amikacin therapy in intensive care unit patients.

Authors:  J Debord; J C Voultoury; G Lachatre; C Gay; J P Favereau; R Gay
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Changes in gentamicin pharmacokinetic profiles induced by mechanical ventilation.

Authors:  C Triginer; I Izquierdo; R Fernández; J Torrent; S Benito; A Net; F Jane
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 4.  Methods of minimising the cost of aminoglycoside therapy to hospitals.

Authors:  C A Gentry; K A Rodvold; J S Bertino
Journal:  Pharmacoeconomics       Date:  1993-03       Impact factor: 4.981

Review 5.  An updated comparison of drug dosing methods. Part III: Aminoglycoside antibiotics.

Authors:  S M Erdman; K A Rodvold; R D Pryka
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

6.  Influence of clinical diagnosis in the population pharmacokinetics of amikacin in intensive care unit patients.

Authors:  S Romano; M Del Mar Fdez de Gatta; V Calvo; E Mendez; A Domínguez-Gil; J M Lanao
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

Review 7.  Aminoglycosides--50 years on.

Authors:  E J Begg; M L Barclay
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

8.  Development of a clinical decision model for thyroid nodules.

Authors:  Alexander Stojadinovic; George E Peoples; Steven K Libutti; Leonard R Henry; John Eberhardt; Robin S Howard; David Gur; Eric A Elster; Aviram Nissan
Journal:  BMC Surg       Date:  2009-08-10       Impact factor: 2.102

Review 9.  Bayesian estimation of pharmacokinetic parameters: an important component to include in the teaching of clinical pharmacokinetics and therapeutic drug monitoring.

Authors:  Dion R Brocks; Dalia A Hamdy
Journal:  Res Pharm Sci       Date:  2020-11-27

10.  A molecular computational model improves the preoperative diagnosis of thyroid nodules.

Authors:  Sara Tomei; Ivo Marchetti; Katia Zavaglia; Francesca Lessi; Alessandro Apollo; Paolo Aretini; Giancarlo Di Coscio; Generoso Bevilacqua; Chiara Mazzanti
Journal:  BMC Cancer       Date:  2012-09-07       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.